On 04 September 2018 DCprime has received approval from the German Paul-Ehrlich-Institute for the ADVANCE-II / DCOne-002 clinical study entitled ‘An international, multicenter, open-label study to evaluate the efficacy and safety of two different vaccination regimens of immunotherapy with allogeneic dendritic cells, DCP-001, in patients with acute myeloid leukaemia that are in remission with persistent MRD’. This multi-center study can now expand its treatment area, next to The Netherlands, also to Germany. The fist clinical site to be activated will be led by Dr. Tobias Holderried from Oncology, Hematology and Rheumatology Department of the University of Bonn.